Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
$1.85
-$0.22(-8.53%)
At close: 4:00 PM EST
$1.85
-$0.22(-8.53%)
Day’s Range― - ―
52-Week Range$0.61 - $11.57
Previous CloseN/A
Volume2.95M
Average Volume (3M)490.26K
Market Cap
$309.11M
Enterprise Value-$79.06M
Total Cash (Recent Filing)$171.53M
Total Debt (Recent Filing)$523.00K
Price to Earnings (P/E)―
Beta2.60
Next Earnings
Mar 11, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding167,089,110
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio-2.58
Price to Book (P/B)5.89
Price to Sales (P/S)0.00
P/FCF Ratio-9.23
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.81
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$9.17Price Target Upside395.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNMRA-215 demonstrated significant body weight reduction both as a monotherapy and in combination with semaglutide, while preserving lean mass and potentially enhancing health, as indicated by improvements in cardiac and endometabolic biomarkers.
Financial PositionNeumora has a cash runway into 2027, beyond the KOASTAL study readouts, Phase I data for NMRA-861, and Phase I data from NMRA-511 without liquidity constraints.
Pipeline DevelopmentThe introduction of NMRA-861, a new candidate for schizophrenia and other neuropsychiatric disorders, has led to an increased price target for the company's stock.
Bears Say
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.61 and its highest was $11.57 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $309.11M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 83 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.333 by -$0.017.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 167,089,110 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.333. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.17 (395.68% Upside)
$9.17 (395.68% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-104.35%
Trailing 12-Months
Asset Growth
-44.66%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
NMRA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a company with a strong pipeline and financial position, with significant upcoming clinical milestones that could create substantial value. However, the continued net loss and competitive challenges in the obesity market were noted as areas of concern.View all NMRA earnings summariesNMRA Stock 12 Month Forecast
Average Price Target
$9.17
▲(395.68% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
I-MAB
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
65.90% Insiders
4.04% Mutual Funds
18.69% Other Institutional Investors
8.20% Public Companies and
Individual Investors